首页 - 股票 - 研报 - 公司研究 - 正文

Non-COVID business to maintain solid growth

来源:招银国际 作者:Jill Wu,Benchen Huang 2023-03-22 15:13:00
关注证券之星官方微博:
(以下内容从招银国际《Non-COVID business to maintain solid growth》研报附件原文摘录)
药明康德(603259)
Strong earnings growth in 2022. WuXi AppTec reported 2022 revenue ofRMB39.4bn, up 72% YoY, attributable recurring net income of RMB8.3bn, up 103% YoY, and attributable adjusted non-IFRS net income of RMB9.4bn, up 83% YoY. The Company delivered resilient growth despite COVID-19 impacts through 2022, with revenue increasing by 71%/ 66%/ 78%/ 72% YoY for 1Q/ 2Q/ 3Q/ 4Q, respectively. Considering the high revenue base of 2022, management guidedpositive revenue growth of 5-7% YoY for 2023E, and reiterated its revenue CAGR target of over 34% in 2021-24E. Specifically for 2023E, management expected revenue of WuXi Chemistry, excluding the commercial-stage COVID-19 project, to maintain a solid growth momentum at 36-38% YoY, the combined revenue of WuXi Testing, WuXi Biology, and WuXi ATU to increase by 20-23% YoY and revenue of DDSU to decline more than 20% due to proactive pipeline adjustment to meet the changing R&D needs of Chinese clients.
Non-COVID projects to fuel sustainable growth. WuXi Chemistry’s revenue increased by 105% YoY in 2022, mainly driven by the 173% YoY revenue growth from its chemical CDMO services. Excluding commercial-stage COVID-19 projects, WuXi Chemistry segment delivered impressive growth of 40% YoY in 2022. Based on our rough estimates, revenue from the COVID-19 projectscould account for ~20% of WuXi AppTec’s total revenue in 2022. We think the solid growth of WuXi AppTec’s business reflected the robust demand from the Company’s extensive and balanced client base amid the temporarily challenging financing environment.
Years’ of investment turning new modalities services into new drivers.Revenue of new modalities-related services (TIDES, mainly including oligo and peptides) jumped by 158% YoY in 2022 to RMB2.0bn, represented ~16% of chemical CDMO revenue (excluding the commercial-stage COVID-19 projects). Moreover, revenue from new modalities within WuXi Biology segment experienced strong YoY growth of 90%, contributing 22.5% of segment revenue in 2022 (vs 14.6% in 2021). The Company has built the largest drug discovery team in the world, functioning as a critical project source for its downstream services, such as CDMO and clinical CRO. More synergies among its various business segments are yet to be released.
Consistent globalization efforts. WuXi AppTec spent RMB10.0bn in Capex in 2022 and plans to invest RMB8-9bn in 2023E to further enhance its global network. In overseas market, the Company is constructing large-scale drug product manufacturing facilities in the US as well as full-suite R&D and manufacturing sites in Singapore with a total investment of US$1.4bn in next 10 years. Its fast-growing global network will enable the Company to better meet the growing and diversified client demand in the ever-changing market.
Maintain BUY. Our TP of RMB121.52 is based on a 10-year DCF model with WACC of 11.57% and terminal growth of 3.0%. We forecast WuXi AppTec’s revenue to grow by 6.9%/ 30.9%/ 26.6% YoY and adjusted non-IFRS net income to grow by 13.5%/ 31.2%/ 25.8% YoY in 2023E/ 24E/ 25E, respectively.





微信
扫描二维码
关注
证券之星微信
APP下载
相关股票:
好投资评级:
好价格评级:
证券之星估值分析提示药明康德盈利能力良好,未来营收成长性良好。综合基本面各维度看,股价偏低。 更多>>
下载证券之星
郑重声明:以上内容与证券之星立场无关。证券之星发布此内容的目的在于传播更多信息,证券之星对其观点、判断保持中立,不保证该内容(包括但不限于文字、数据及图表)全部或者部分内容的准确性、真实性、完整性、有效性、及时性、原创性等。相关内容不对各位读者构成任何投资建议,据此操作,风险自担。股市有风险,投资需谨慎。如对该内容存在异议,或发现违法及不良信息,请发送邮件至jubao@stockstar.com,我们将安排核实处理。
网站导航 | 公司简介 | 法律声明 | 诚聘英才 | 征稿启事 | 联系我们 | 广告服务 | 举报专区
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-